{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-126342","form_type":"8-K","ticker":"KYTX","cik":"0001994702","company_name":"Kyverna Therapeutics, Inc.","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.532787+00:00","generated_at":"2026-05-30T01:20:30.574436+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Kyverna Q3 net loss $34.3M; CMO James Chung resigns effective Nov 22","bullets":["Net loss of $34.3M ($0.80 per share) vs. $15.5M loss in prior-year quarter.","Cash, equivalents and marketable securities $321.6M as of Sep 30, 2024.","CMO James Chung, M.D., Ph.D. resigns effective Nov 22; search for replacement underway.","CEO Warner Biddle appointed; Board adds Christi Shaw and Mert Aktar.","KYV-101 advances: Phase 2 dosing in myasthenia gravis; RMAT and Orphan Drug designations in multiple indications."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-126342","json":"https://secwatch.observer/filing/0000950170-24-126342.json","markdown":"https://secwatch.observer/filing/0000950170-24-126342.md","text":"https://secwatch.observer/filing/0000950170-24-126342.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1994702/000095017024126342/0000950170-24-126342-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1994702/000095017024126342/kytx-20241108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:20:30.574436+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4c2ff182cc","claim":"James Chung resigned as Chief Medical Officer at Kyverna Therapeutics, Inc..","evidence_excerpt":"On November 8, 2024, James Chung, M.D., Ph.D., Chief Medical Officer of the Company, resigned from the Company, to be effective as of November 22, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1994702/000095017024126342/0000950170-24-126342-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}